Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 7/20 | 0.59 |
| ▸ | ADA | P00813 | 1/20 | 0.55 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | PI4KA | P42356 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962598 | 1.00 | AHCY (0.59) | AHCYADASTING1TP53CYP2C9 | |
| SCHEMBL20794222 | 1.00 | AHCY (0.59) | AHCYADASTING1TP53CYP2C9 | |
| SCHEMBL29362124 | 1.00 | AHCY (0.59) | AHCYADASTING1TP53CYP2C9 | |
| SCHEMBL10015774 | 1.00 | AHCY (0.59) | AHCYADASTING1TP53CYP2C9 | |
| SCHEMBL896624 | 1.00 | AHCY (0.59) | AHCYADASTING1TP53CYP2C9 | |
| SCHEMBL23396436 | 1.00 | AHCY (0.59) | AHCYADASTING1TP53CYP2C9 | |
| SCHEMBL5962596 | 1.00 | AHCY (0.59) | AHCYADASTING1TP53CYP2C9 | |
| SCHEMBL13986298 | 0.87 | AHCY (0.57) | AHCYADASTING1TP53CYP2C9 | |
| SCHEMBL17833855 | 0.87 | AHCY (0.62) | AHCYADASTING1TP53CYP2C9 | |
| SCHEMBL13986311 | 0.87 | AHCY (0.57) | AHCYADASTING1TP53CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268901-B2 | Targeting cell tropism receptors to inhibit cytomegalovirus infection | UNIVERSITY OF MASSACHUSETTS (US) | 2025-04-08 | — | — | US | claimed |
| CN-118186099-A | Method for jointly verifying dopamine signaling pathway by using nematodes and human cells | 上海大学 | 2024-06-14 | — | — | CN | claimed |
| US-20230034732-A1 | TARGETING CELL TROPISM RECEPTORS TO INHIBIT CYTOMEGALOVIRUS INFECTION | UNIVERSITY OF MASSACHUSETTS | 2023-02-02 | — | — | US | claimed |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | claimed |
| EP-3833336-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) | 2021-06-16 | — | — | EP | claimed |
| CN-112888432-A | Methods for delaying the onset of new onset type 2 diabetes and for slowing the progression of type 2 diabetes and treating type 2 diabetes | 英国达科(莱得海德)制药有限公司-楚歌分公司 | 2021-06-01 | — | — | CN | claimed |
| US-10912786-B2 | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same | CORNELL UNIVERSITY (US) | 2021-02-09 | — | — | US | claimed |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | claimed |
| US-20200376077-A1 | Targeting Cell Tropism Receptors to Inhibit Cytomegalovirus Infection | UNIVERSITY OF MASSACHUSETTS | 2020-12-03 | — | — | US | claimed |
| US-20200276312-A1 | Elimination of chronic pain by chronic activation of adenosine receptor type A1 in peripheral sensory neurons | UNIV ROCHESTER (US) | 2020-09-03 | — | — | US | claimed |
| US-20060099568-A1 | Signals and molecular species involved in senescence | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2006-05-11 | — | — | US | claimed |
| WO-2005092306-A1 | METHODS AND COMPOSITIONS FOR MODULATING OPIOID TOLERANCE AND CHRONIC PAIN | THE GENERAL HOSPITAL CORPORATION (US) | 2005-10-06 | — | — | WO | claimed |
| EP-1557461-A1 | COMPOSITION FOR CULTURING MULTIPOTENT STEM CELLS AND UTILIZATION OF THE SAME | RIKEN (JP) | 2005-07-27 | — | — | EP | claimed |
| EP-1542687-A1 | SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2005-06-22 | — | — | EP | claimed |
| WO-2004028538-A1 | SMALL ORGANIC MOLECULES THAT INCREASE THE ACTIVITY OF GELATINASE A IN OCULAR CELLS | BAUSCH & LOMB INCORPORATED (US) | 2004-04-08 | — | — | WO | claimed |
| US-20040068017-A1 | Small organic molecules that increase the activity of Gelatinase A in ocular cells | BAUSCH & LOMB INCORPORATED | 2004-04-08 | — | — | US | claimed |
| WO-2004006832-A2 | METHODS AND COMPOUNDS FOR REDUCING BIOFILM FORMATION | ROMEO TONY (US) | 2004-01-22 | — | — | WO | claimed |
| US-20040009927-A1 | Methods and compounds for reducing biofilm formulation | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTRE AT FORT WORTH | 2004-01-15 | — | — | US | claimed |
| WO-2003104482-A1 | SIGNALS AND MOLECULAR SPECIES INVOLVED IN SENESCENCE | METABOLIC ENGINEERING LABORATORIES CO., LTD. (KR) | 2003-12-18 | — | — | WO | claimed |
| US-6429208-B1 | ADMINISTERING 2',5'-DIDEOXYADENOSINE TO INHIBIT PROTEIN KINASE A/CYCLIC ADENOSINE MONOPHOSPHATE PATHWAY; REVERSES EFFECTS OF HIV INFECTION; ALLOWS FOR LYMPHOCYTE PROLIFERATION | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-08-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040068017-A1 | Small organic molecules that increase the activity of Gelatinase A in ocular cells | MMP1, MMP3, MMP10 | AHCY 4194/4885ADA 4178/4885STING1 4297/4885 |
| US-10912786-B2 | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same | STIM1, STAMBP, ILK | AHCY 1970/4885ADA 4822/4885STING1 3739/4885 |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | AHCY 388/4885ADA 348/4885STING1 3142/4885 |
| US-20200276312-A1 | Elimination of chronic pain by chronic activation of adenosine receptor type A1 in peripheral sensory neurons | P2RX3, P2RX1, P2RX2 | AHCY 1773/4885ADA 397/4885STING1 928/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | AHCY 2493/4885ADA 2606/4885STING1 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.